Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep750 | Pituitary: clinical | ECE2015

Rate of Prolactin suppression can predict future prolactin normalisation, tumour shrinkage and time to remission in male macroprolactinomas

Tirosh Amit , Benbassat Carlos , Shimon Ilan

Introduction: Dopamine agonists are the mainstay treatment for prolactinomas, but clinical characteristics that predict their effects on prolactin (PRL) suppression and tumour shrinkage are missing. Our study aimed to find measures in early follow-up of men harbouring macroprolactinomas, that will predict dynamics of PRL decrease and adenoma shrinkage.Methods: A single centre historical prospective study, including a consecutive group of 71 men with pitu...

ea0056gp79 | Diabetes Complications | ECE2018

Outcomes of hyperglycemia in patients with and without diabetes mellitus hospitalized for infectious diseases

Gorshtein Alexander , Shimon Ilan , Akirov Amit

Context: Hyperglycemia is common among patients with and without diabetes mellitus (DM) hospitalized for infectious diseases. The long-term outcomes of hyperglycemia have not been adequately studied in this population.Objective: Examine the prognostic implications of hyperglycemia and the importance of glycemic control in patients with and without DM during hospitalization for infectious diseases.Methods: Historical prospectively c...

ea0016p483 | Neuroendocrinology | ECE2008

mTOR inhibitors rapamycin and RAD001 (Everolimus) induce antiproliferative effects in GH3 cell line and human pituitary adenomas

Rubinfeld Hadara , Gorshtein Alexander , Kendler Efrat , Hadani Moshe , Shimon Ilan

The effect of mTOR inhibitors on pituitary tumors is unknown. Akt overexpression was demonstrated in pituitary adenomas, which may render them sensitive to the antiproliferative effects of these drugs.To evaluate the in vitro effects of mTOR inhibitor rapamycin, and its orally-bioavailable analog RAD001 on pituitary cells, GH3 cells, a mammosomatotroph rat pituitary tumor cell line, and human GH-secreting and non-functioning pituitary adenoma (NFP...

ea0081p653 | Pituitary and Neuroendocrinology | ECE2022

Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma

Rudman Yaron , Duskin-Bitan Hadar , Masri-Iraqi Hiba , Akirov Amit , Shimon Ilan

Objective: To study the baseline characteristics predicting hypogonadotropic hypogonadism (HH) persistence in men with macroprolactinoma following medical treatment with cabergoline.Design: Retrospective cohort study conducted in a tertiary pituitary center.Methods: Male patients diagnosed with macroprolactinoma and HH that received cabergoline treatment with subsequent prolactin normalization were included: men that achieved eugon...

ea0063gp119 | Diabetes: Late Complications | ECE2019

Glycemic variability and mortality in patients hospitalized to general surgery wards

Gorshtein Alexander , Shochat Tzipora , Dotan Idit , Diker-Cohen Talia , Shimon Ilan , Akirov Amit

Background: Glucose variability (GV) is common among hospitalized patients but the prognostic implications among patients hospitalized to surgical wards are unknown.Objective: Investigate the association between GV, length of stay (LOS) and mortality.Methods: Historical prospectively collected data of patients ≥18 years, hospitalized to general surgery wards between January 2011–December 2017. GV was assessed by coeffici...

ea0063p750 | Thyroid 2 | ECE2019

Presentation of thyrotoxicosis in hospitalized elderly patients

Duskin-Bitan Hadar , Adler-Cohen Chagit , Ferder Ayelet , Shimon Ilan , Grossman Alon

Introduction: Thyrotoxicosis in the elderly may present differently than in younger indeviduals, and with the aging of the worlds’ population it is imperative to obtain data in this age group.Aim: Our aim was to identify and characterize clinical and biochemical parameters of thyrotoxicosis in the elderly and to compare them to those of younger patients.Methods: We retrospectively evaluated files of patients older than 40 who ...

ea0070aep205 | Bone and Calcium | ECE2020

Denosumab-induced hypocalcemia: Does gender play a role?

Diker-Cohen Talia , Amitai Oren , Shochat Tzippy , Shimon Ilan , Tsvetov Gloria

Introduction: The recognition that disease presentation, treatment and outcomes may differ betweenmen and women has become established. We have recently reported a-7.4% rate of denosumab-associated hypocalcemia in community-dwelling osteoporotic patients.Aim: To investigate the role of gender in this complication.Methods: A retrospective analysis of medical records (2010–2018) from a large HMO. An albumin-adjusted serum calci...

ea0070aep696 | Pituitary and Neuroendocrinology | ECE2020

Long-term response to cabergoline treatment in men with macroprolactinoma is independent of tumor size

Rudman Yaron , Duskin-Bitan Hadar , Pertzov Barak , Manisterski Yossi , Masri-Iraqi Hiba , Shimon Ilan

Objective: To study the outcomeof menwith macroprolactinoma followingcabergoline treatment based on tumor size.Design: A retrospective cohort study using a single tertiary referral center registry.Methods: The study included 96 men with macroprolctinoma, aged 16–84 years (mean 47.3 years) treated from 1993 to 2019,for a mean follow-up of 7.5 years. The cohort was subdivided into 3 groups according to baseline adenoma diameter...

ea0081rc7.3 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Pituitary microadenoma vs macroadenomas in cushing’s disease: does size matter?

Akirov Amit , Shimon Ilan , Yosi Manisterski , Aviran-Barak Nirit , Nadler Varda , Alboim Sandra , Kopel Vered , Tsvetov Gloria , Hirsch Dania

Background: The majority of adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas are less than 10 mm in diameter and are described as microadenomas, while corticotroph macroadenomas (≥10 mm) are a less common cause of Cushing’s disease. Prior reports on the differences of clinical and biochemical behavior of corticotroph microadenomas and macroadenomas were inconsistent.Objective: Describe the clinical and biochemical characteristic...

ea0081p255 | Late-Breaking | ECE2022

Cushing syndrome in older women: age-related differences in disease origin and clinical manifestations

Akirov Amit , Shimon Ilan , Yosi Manisterski , Aviran-Barak Nirit , Nadler Varda , Alboim Sandra , Tsvetov Gloria , Hirsch Dania

Background: Adrenocorticotropic hormone (ACTH)-producing pituitary adenoma is the most common cause of endogenous Cushing syndrome (CS), but the relative proportion of adrenal causes of CS is rising. Limited data are available on the clinical manifestations and cause of CS in older women.Objective: Determine the clinical presentation, biochemical profile, and cause of CS in women 65 years of age and older, compared with younger patients with CS.<p cl...